Xencor, Inc.
Pasadena, California, United States
Matthew Bernett, Ph.D. has been at Xencor, Inc. for over 19 years, and is currently an Executive Director in the Protein Engineering group where he has been involved in all aspects of the company’s research efforts. Accomplishments include being a co-inventor of tafasitamab (Monjuvi) as well as Xencor’s bispecific platform of T-cell engaging and immune-oncology bispecifics, leading to over ten programs currently in clinical development. He has deep experience in protein and antibody engineering, drug development (from idea to clinic), and internal and external team leadership including multiple collaborations with external partners such as Genentech and Amgen.
0010: XmAb657, a CD19 x CD3 T-Cell Engaging Bispecific Antibody for Autoimmune Disease
Sunday, October 26, 2025
10:30 AM - 12:30 PM Central Time
Disclosure(s): Xencor, Inc.: Employee (Ongoing), Equity interest (Ongoing), Intellectual Property/Patents (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing)
